Suzanne L. Topalian, MD

Suzanne L. Topalian, MD

Associate Director
Bloomberg-Kimmel Institute for Cancer Immunotherapy and Professor of Surgery
Johns Hopkins University School of Medicine
Baltimore, Maryland

Dr. Topalian is the Bloomberg-Kimmel professor of cancer immunotherapy at Johns Hopkins University School of Medicine. She is a physician-scientist whose studies have been foundational in developing cancer immunotherapy. She trained at Tufts University School of Medicine, Thomas Jefferson University Hospital, and the National Cancer Institute, after which she was a senior investigator at the NCI. She joined Johns Hopkins in 2006, leading its Melanoma Program. Her research focuses on manipulating “immune checkpoints” such as PD-1 in cancer therapy. She was named one of Nature’s 10 in 2014, received ASCO’s Karnofsky Award in 2015 and the Taubman Prize in 2016, and was elected to the National Academy of Medicine in 2017, for landmark discoveries in immunotherapy. Her work has opened new avenues of investigation and supported the establishment of immunotherapy as a pillar of oncology.